These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18627399)

  • 41. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
    Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
    J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Up-regulation of Th1-type responses in mucosal leishmaniasis patients.
    Bacellar O; Lessa H; Schriefer A; Machado P; Ribeiro de Jesus A; Dutra WO; Gollob KJ; Carvalho EM
    Infect Immun; 2002 Dec; 70(12):6734-40. PubMed ID: 12438348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy.
    Pratti JES; da Fonseca Martins AM; da Silva JP; Ramos TD; Pereira JC; Firmino-Cruz L; Oliveira-Maciel D; Vieira TSS; Lacerda LL; Vale AM; Freire-de-Lima CG; Gomes DCO; Saraiva EM; Rossi-Bergmann B; de Matos Guedes HL
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007146. PubMed ID: 30802247
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major.
    Kemp M; Handman E; Kemp K; Ismail A; Mustafa MD; Kordofani AY; Bendtzen K; Kharazmi A; Theander TG
    FEMS Immunol Med Microbiol; 1998 Mar; 20(3):209-18. PubMed ID: 9566492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis.
    De Luca PM; Mayrink W; Pinto JA; Coutinho SG; Santiago MA; Toledo VP; Costa CA; Genaro O; Reis AB; Mendonça SC
    Acta Trop; 2001 Dec; 80(3):251-60. PubMed ID: 11700183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune response to Leishmania antigen in anthroponotic cutaneous leishmaniasis.
    Ajdary S; Riazi-Rad F; Alimohammadian MH; Pakzad SR
    J Infect; 2009 Aug; 59(2):139-43. PubMed ID: 19560211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chitosan Nanoparticles Loaded with Whole and Soluble Leishmania Antigens, and Evaluation of Their Immunogenecity in a Mouse Model of Leishmaniasis.
    Hojatizade M; Soleymani M; Tafaghodi M; Badiee A; Chavoshian O; Jaafari MR
    Iran J Immunol; 2018 Dec; 15(4):281-293. PubMed ID: 30593742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune responses induced by a Leishmania (Leishmania) amazonensis recombinant antigen in mice and lymphocytes from vaccinated subjects.
    Fernandes AP; Herrera EC; Mayrink W; Gazzinelli RT; Liu WY; de Costa CA; Tavares CA; Melo MN; Michalick MS; Gentz R; Nascimento E
    Rev Inst Med Trop Sao Paulo; 1997; 39(2):71-8. PubMed ID: 9394518
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis.
    Kemp M; Hey AS; Kurtzhals JA; Christensen CB; Gaafar A; Mustafa MD; Kordofani AA; Ismail A; Kharazmi A; Theander TG
    Clin Exp Immunol; 1994 Jun; 96(3):410-5. PubMed ID: 8004809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis.
    Salgado CL; Dias EL; Stringari LL; Covre LP; Dietze R; Lima Pereira FE; de Matos Guedes HL; Rossi-Bergmann B; Gomes DCO
    Microbes Infect; 2019; 21(7):328-335. PubMed ID: 30817996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Leishmanin skin test lymphoproliferative responses and cytokine production after symptomatic or asymptomatic Leishmania major infection in Tunisia.
    Sassi A; Louzir H; Ben Salah A; Mokni M; Ben Osman A; Dellagi K
    Clin Exp Immunol; 1999 Apr; 116(1):127-32. PubMed ID: 10209516
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leishmania (Leishmania) amazonensis-induced cutaneous leishmaniasis in the primate Cebus apella: a model for vaccine trials.
    Garcez LM; Goto H; Ramos PK; Brigido Mdo C; Gomes PA; Souza RA; De Luca PM; Mendonça SC; Muniz JA; Shaw JJ
    Int J Parasitol; 2002 Dec; 32(14):1755-64. PubMed ID: 12464422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of inflammatory, anti-inflammatory, and regulatory cytokines in patients infected with cutaneous leishmaniasis in Amazonas State, Brazil.
    Espir TT; Figueira Lde P; Naiff Mde F; da Costa AG; Ramalho-Ortigão M; Malheiro A; Franco AM
    J Immunol Res; 2014; 2014():481750. PubMed ID: 25295285
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic application of recombinant Leishmania proteins and evaluation of their in vitro immunogenicity after stimulation of immune cells collected from tegumentary leishmaniasis patients and healthy individuals.
    Lima MP; Costa LE; Lage DP; Dias DS; Ribeiro PAF; Machado AS; Ramos FF; Salles BCS; Fagundes MI; Carvalho GB; Franklin ML; Chávez-Fumagalli MA; Machado-de-Ávila RA; Menezes-Souza D; Duarte MC; Teixeira AL; Gonçalves DU; Coelho EAF
    Cell Immunol; 2018 Dec; 334():61-69. PubMed ID: 30287082
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Schistosoma mansoni antigens alter the cytokine response in vitro during cutaneous leishmaniasis.
    Bafica AM; Cardoso LS; Oliveira SC; Loukas A; Varela GT; Oliveira RR; Bacellar O; Carvalho EM; Araújo MI
    Mem Inst Oswaldo Cruz; 2011 Nov; 106(7):856-63. PubMed ID: 22124559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
    Vilela Mde C; Gomes DC; Marques-da-Silva Ede A; Serafim TD; Afonso LC; Rezende SA
    Acta Trop; 2007; 104(2-3):133-9. PubMed ID: 17919443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.